Ovarian cancer trials in Japan

In Japan 48 Also abroad 794

48 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Where
Akashi, Gunma, Kagoshima, Koto-ku, Kure, Minato-ku, Tokyo, Okayama, Sapporo, Sendai, Shinjuku-ku, Shiwa-gun, Tōon
Age
18 years and over
People
880 worldwide
Run by
NRG Oncology
See details and how to joinNCT06580314
Phase 3Taking people
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Where
Fukushima, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kawasaki-shi, Kobe, Kōtoku, Kurume-shi, Kyoto, Minatoku, Nagoya, Niigata, Osaka, Ota-shi, Sagamihara-shi, Sapporo, Sendai, Shinjuku-ku, Shiwa-gun, Suita, Sunto-gun, Toon-Shi, Tsu, Yokohama
Age
18 years and over
People
950 worldwide
Run by
AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00
Phase 1/2Taking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Akashi, Fukushima, Hidaka, Koto, Nagaizumi-chō, Ōta, Sapporo, Shinjuku-ku, Yamagata
Age
18 years and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
Phase 3Taking people
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Where
Akashi, Gunma, Hiroshima, Koto-ku, Kyoto, Matsuyama, Okayama, Saitama, Sapporo, Showa-Ku Nagoya, Tokyo, Tōon
Age
18 years to 60 years
People
3,960 worldwide
Run by
NRG Oncology
See details and how to joinNCT05879926
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Shizuoka, Tokyo
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Chuo Ku, Kashiwa, Koto-ku, Nagoya, Sakai, Sapporo
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 1Taking people
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Where
Chiba, Kyoto
Age
18 years and over
People
340 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00
Phase 3Taking people
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Where
Akashi, Chūōku, Fukuoka, Hidaka, Kagoshima, Kashiwa, Kōtoku, Nagoya, Niigata, Okayama, Otashi, Sapporo, Sendai, Shiwa-gun Yahaba-cho, Suita, Tōon, Tsu
Age
18 years and over
People
1,630 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Where
Chuo Ku Niigata, Tokushima, Tokyo, Yamagata
Age
18 years and over
People
688 worldwide
Run by
Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00
Phase 3Taking people
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
Where
Niigata, Osaka
Age
18 years and over
People
720 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07694427 · EU 2025-523365-13-00
Phase 3Taking people
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Where
Aichi, Miyagi, Osaka, Tokyo, Tsu
Age
18 years and over
People
270 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
Akashi, Fukushima, Hidaka, Kōtoku, Kurume, Nagoya, Nakatogari, Niigata, Okayama, Osaka, Sapporo, Tokyo, Tsu, Yahaba-cho, Yamagata
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 2/3Taking people
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Where
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kōtoku, Minatoku, Nagaizumi-chō, Nagoya, Niigata, Okayama, Osaka, Sapporo, Shiwa-gun
Age
18 years and over
People
860 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Hidaka, Kagoshima, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-chō, Nagoya, Osakasayama-Shi, Saitama, Tokyo, Yokohama
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Chuo Ku, Kashiwa, Koto-ku, Matsuyama, Nagaizumi-chō, Nagoya, Ōsaka-sayama, Saitama
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1Taking people
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Where
Tokyo
Age
18 years and over
People
138 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07360314 · EU 2025-523232-39-00
Phase 3Taking people
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Where
Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe, Kōtoku, Kurume-shi, Kyoto, Minatoku, Natori-shi, Sagamihara-shi, Shinjuku-ku, Suita-shi, Toyoake-shi, Yokohama
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00
Phase 1/2Taking people
SMP-3124LP in Adults With Advanced Solid Tumors
Where
Kashiwa-shi, Kyoto
Age
18 years and over
People
120 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT06526819
Phase 3Taking people
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Where
Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Minatoku, Nagoya, Okayama, Osaka, Sapporo, Sendai, Shiwa-gun, Shizuoka, Tokyo
Age
18 years and over
People
466 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00
Phase 3Taking people
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Where
Fukuoka, Hokkaido, Hyōgo, Kanagawa, Mie, Okinawa, Osaka, Saitama, Tottori
Age
18 years and over
People
450 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07286266 · EU 2025-523361-25-00
Phase 1Taking people
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Where
Chuo-Ku, Kashiwa-shi, Koto-ku, Kyoto, Nagoya, Sunto-gun
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Chūōku, Hidaka-shi, Kashiwa, Kōtoku, Kurume-shi, Sunto-gun
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Where
Fukuoka, Hidaka, Kagoshima, Kashiwa, Koto, Kurume, Matsuyama, Nagoya, Niigata, Osaka, Ōta, Sapporo, Shinjyuku, Shiwa-gun, Sunto-gun,, Tōon
Age
18 years and over
People
770 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00
Phase 1Taking people
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Where
Hidaka, Kashiwa-shi, Sunto-gun
Age
18 years and over
People
285 worldwide
Run by
AbbVie
See details and how to joinNCT07278336 · EU 2025-522209-40-00